Document is current
Any future updates will be listed below
-
Authors
Richards, Alexsia
Khalil, Andrew S.
Friesen, Max https://orcid.org/0000-0002-6699-6619
Whitfield, Troy W. https://orcid.org/0000-0002-2026-4201
Gao, Xinlei
Lungjangwa, Tenzin
Kamm, Roger D. https://orcid.org/0000-0002-7232-304X
Wan, Zhengpeng
Gehrke, Lee
Mooney, David https://orcid.org/0000-0001-6299-1194
Jaenisch, Rudolf https://orcid.org/0000-0002-2540-7099
- License Information
-
More Information
Article History
Received: 6 August 2023
Accepted: 22 November 2024
First Online: 30 December 2024
Competing interests
: The authors declare the following competing interests. R.J. is an advisor/co-founder of Fate Therapeutics and Fulcrum Therapeutics. D.J.M. has sponsored research, consults, and/or has stock options/stock in Medicenna, Lyell, Attivare, Epoulosis, Limax Biosciences, Lightning Bio, and Oddity Tech, licensed intellectual property with Alkem and Amend Surgical, and Board of Directors, ATCC.The remaining authors (A.R., A.K., T.W., M.F., X.G., L.G., R.K., T.L., Z.W.) declare no competing interests.
